Skip to main content
Caplight Logo









STRM.BIO

STRM.BIO

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://strm.bio/

Last Round

Series 2

Jan 7, 2026

Total Funding Raised

$18.66M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

STRM.BIO is a biotechnology company that is developing a proprietary extracellular vesicle (EV) platform to deliver gene therapies directly to patients.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Government Contracts

AI Layer

Non-AI

Keywords

extracellular vesiclesgene therapy deliverynon-viral deliveryin vivo deliverygenetic medicinebiotech platformdrug deliverygene therapycell therapydelivery vehicleEV deliverybiotech R&Dgenetic payloadtargeted deliverynext-gen therapeutics

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

STRM.BIO Comparables

Compare STRM.BIO with similar companies based on industry and business-model similarity.

STRM.BIO comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Carmine Therapeutics
85%
Neucore Bio
80%
Code Biotherapeutics
80%

STRM.BIO Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series 2Jan 7, 2026
GrantDec 3, 2025
GrantOct 3, 2023
GrantJul 26, 2022
SeedMar 31, 2021

Key People

Founding team and executive leadership

Michael Luther

Chief Executive Officer And Board Of Directors

Executive Team

Rob Hughes

CFO

Executive Team

David Raiser

Chief Operating Officer

Executive Team

STRM.BIO Investors

Notable investors and investment history

STRM.BIO investors
InvestorRounds
Ascension VenturesSeed
The EngineSeed
NIH RADxGrant
GaingelsSeed
Alix VenturesSeed
Gates FoundationGrant
Breakout VenturesSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 7, 2026

    Raised $8M led by Recordati SpA.

  • Dec 3, 2025

    Awarded contract from ARPA-H for non-viral delivery technologies.

STRM.BIO Filings

Explore SEC and related filing metadata, where available.

STRM.BIO filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about STRM.BIO's valuation, stock price, and market status.

Is STRM.BIO a public or private company?

STRM.BIO is a private company.

What is the current stock price of STRM.BIO?

STRM.BIO is a private company with no public stock price. No recent secondary market data is available.

How much is STRM.BIO worth (valuation)?

Valuation information for STRM.BIO is not publicly available.

Can I buy STRM.BIO stock?

STRM.BIO shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was STRM.BIO's last funding round?

STRM.BIO's most recent funding round was Series Seed 2 on December 1, 2025.

Who are the main investors in STRM.BIO?

Key investors in STRM.BIO include Ascension Ventures, The Engine, Gaingels, Alix Ventures, Breakout Ventures.

Will STRM.BIO IPO soon?

No public IPO plans have been announced for STRM.BIO.

How can I track STRM.BIO secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor STRM.BIO's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range17
Year Founded2019
Last FundingJan 7, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?